Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, has unveiled plans to invest $30 million at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services. The project is being supported by the Prefecture of Haute-Vienne, the Metropolitan Area of Limoges, the Limoges Ha...